Page 2289 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 136 Inhibitors in Hemophilias 2033.e3

88. Hay CR, Brown S, Collins PW, et al: The diagnosis and management 108. Negrier C, Goudemand J, Sultan Y, et al: Multicenter retrospective
of factor VIII and IX inhibitors: A guideline from the United Kingdom study on the utilization of FEIBA in France in patients with factor
Haemophilia Centre Doctors Organisation. Br J Haematol 133:591, VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight
2006. Bypassing Activity. Thromb Haemost 77:1113, 1997.
89. Scalone L, Mantovani LG, Mannucci PM, et al: Quality of life is associ- 109. Tjonnfjord GE: Surgery in patients with hemophilia and inhibitors:
ated to the orthopaedic status in haemophilic patients with inhibitors. A review of the Norwegian experience with FEIBA. Semin Hematol
Haemophilia 12:154, 2006. 43:S18, 2006.
90. Gringeri A, Mantovani LG, Scalone L, et al: Cost of care and quality 110. Leissinger C, Gringeri A, Antmen B, et al: Anti-inhibitor coagulant
of life for patients with hemophilia complicated by inhibitors: The complex prophylaxis in haemophilia with inhibitors. N Engl J Med
COCIS Study Group. Blood 102:2358, 2003. 365:1684, 2011.
91. Darby SC, Keeling DM, Spooner RJ, et al: The incidence of factor 111. Hedner U, Kisiel W: Use of human factor VIIa in the treatment of two
VIII and factor IX inhibitors in the hemophilia population of the UK hemophilia A patients with high-titer inhibitors. J Clin Invest 71:1836,
and their effect on subsequent mortality, 1977-99. J Thromb Haemost 1983.
2:1047, 2004. 112. Lusher JM, Roberts HR, Davignon G, et al: A randomized, double-
92. Kasper CK, Aledort L, Aronson D, et al: Proceedings: A more uniform blind comparison of two dosage levels of recombinant factor VIIa in the
measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:612, treatment of joint, muscle and mucocutaneous haemorrhages in persons
1975. with haemophilia A and B, with and without inhibitors. rFVIIa Study
93. Verbruggen B, Novakova I, Wessels H, et al: The Nijmegen modifica- Group. Haemophilia 4:790, 1998.
tion of the Bethesda assay for factor VIII: C inhibitors—improved 113. Shapiro AD, Gilchrist GS, Hoots WK, et al: Prospective, randomised
specificity and reliability. Thromb Haemost 73:247, 1995. trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with
94. Giles AR, Verbruggen B, Rivard GE, et al: A detailed comparison of inhibitors undergoing surgery. Thromb Haemost 80:773, 1998.
the performance of the standard versus the Nijmegen modification of 114. Astermark J, Donfield SM, Dimichele DM, et al: A randomized com-
the Bethesda assay in detecting factor VIII: C inhibitors in the hae- parison of bypassing agents in hemophilia complicated by an inhibitor:
mophilia A population of Canada. Association of Hemophilia Centre The FEIBA NovoSeven Comparative (FENOC) Study. Blood 109:546,
Directors of Canada. Factor VIII/IX Subcommittee of Scientific and 2007.
Standardization Committee of International Society on Thrombosis 115. Young G, Shafer FE, Rojas P, et al: Single 270 microg kg(-1)-dose
and Haemostasis. Thromb Haemost 9:872, 1998. rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home
95. Kershaw GW, Chen IS, Jayakodi D, et al: Validation of 4% albumin treatment of joint bleeds in haemophilia patients with inhibitors: a
as a diluent in the Bethesda Assay for FVIII inhibitors. Thromb Res randomized comparison. Haemophilia 14:287, 2008.
132:735–741, 2013. 116. Shapiro AD, Neufeld EJ, Cooper DL: Safety and exposure to recombi-
96. Kitchen S, Jennings I, Preston FE, et al: Interlaboratory variation in nant activated FVII doses in patients with haemophilia and inhibitors
Factor VIIc Inhibitor assay results is sufficient to influence patient to FVIII or IX. Blood 116:1508, 2010.
management: data from the UK national quality external assessment 117. Faranoush M, Abolghasemi H, Mahboudi F, et al: A comparison of
scheme for blood coagulation. Semin Thromb Hemost 35:778, 2009. efficacy between recombinant activated factor VII (Aryoseven) and
97. Vincent AM, Lillicrap D, Tuttle A, et al: Assay of factor VIII inhibitors Novoseven in patients with hereditary FVIII deficiency with inhibitor.
by ELISA using plasma specimens dried on filter paper and stored at Clin App Thromb Hemost 22:184, 2016.
room temperature. Blood 114:1350, 2009. 118. Deleted in review.
98. Zakarija A, Harris S, Rademaker AW, et al: Alloantibodies to factor VIII 119. Schneiderman J, Nugent DJ, Young G: Sequential therapy with
in haemophilia. Haemophilia 17:636, 2011. activated prothrombin complex concentrate and recombinant factor
99. Gilles JG, Arnout J, Vermylen J, et al: Anti-factor VIII antibodies of VIIa in patients with severe haemophilia and inhibitors. Haemophilia
hemophiliac patients are frequently directed towards nonfunctional 10:347, 2004.
determinants and do not exhibit isotypic restriction. Blood 82:2452, 120. Martinowitz U, Livnat T, Zivelin A, et al: Concomitant infusion of low
1993. doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
100. Hay CR, Brown S, Collins PW, et al: The diagnosis and management Haemophilia 15:904, 2009.
of factor VIII and IX inhibitors: A guideline from the United Kingdom 121. Bringeri A, Fisher K, Karafoulidou A, et al: Sequential combined
Haemophilia Centre Doctors Organisation. Br J Haematol 133:591, bypassing therapy (SCBT) is safe and effective in the treatment of
2006. unresponsive bleeding in adults and children with hemophilia and
101. Ingerslev J: Hemophilia. Strategies for the treatment of inhibitor inhibitors. Blood 114:531, 2009.
patients. Haematologica 85:15, 2000. 122. Shima M: Understanding the hemostatic effects of recombinant factor
102. Hay CR, Baglin TP, Collins PW, et al: The diagnosis and management VIIa by clot wave form analysis. Semin Hematol 41:125, 2011.
of factor VIII and IX inhibitors: A guideline from the UK Haemophilia 123. Young G, Blain R, Nakagawa P, et al: Individualization of bypassing
Centre Doctors’ Organization (UKHCDO). Br J Haematol 111:78, agent treatment for haemophilic patients with inhibitors utilizing
2000. thromboelastography. Haemophilia 12:598, 2006.
103. Hay CR, Brown S, Collins PW, et al: The diagnosis and management 124. Ingerslev J, Sorensen B: Parallel use of of by-passing agents in haemo-
of factor VIII and IX inhibitors: A guideline from the United Kingdom philia with inhibitors: a critical review. Br J Haematol 155:256, 2011.
Haemophilia Centre Doctors Organisation. Br J Haematol 133:591, 125. Konkle B, Ebbesen LS, Erhardtsen E: Randomized, prospective clinical
2006. trial of recombinant factor VIIa for secondary prophylaxis in haemo-
104. Gringeri A, Mannucci PM: Italian guidelines for the diagnosis and philia patients with inhibitors. J Thromb Haemost 5:1904, 2008.
treatment of patients with haemophilia and inhibitors. Haemophilia 126. Jimenez-Yuste V, Alvarez MT, Martin-Salces M, et al: Prophylaxis in 10
11:611, 2005. patients with severe haemophilia A and inhibitor: different approaches
105. Lusher JM, Shapiro SS, Palascak JE, et al: Efficacy of prothrombin- for different clinical situations. Haemophilia 15:203, 2009.
complex concentrates in hemophiliacs with antibodies to factor VIII: 127. Ghosh K, Shetty S, Jijina F, et al: Role of epsilon aminocaproic acid in
A multicenter therapeutic trial. N Engl J Med 303:421, 1980. the management of haemophilic patients with inhibitors. Haemophilia
106. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al: The effect 10:58, 2004.
of activated prothrombin-complex concentrate (FEIBA) on joint and 128. Kruse-Jarres R, St-Louis J, Greist A, et al: Efficacy and safety of OBI-1,
muscle bleeding in patients with hemophilia A and antibodies to factor an antihaemophilic factor VIII (recombinant), porcine sequence, in
VIII. A double-blind clinical trial. N Engl J Med 305:717, 1981. subjects with acquired haemophilia A. Haemophilia 21:162–170,
107. Hilgartner MW, Knatterud GL: The use of factor eight inhibitor 2015.
by-passing activity (FEIBA immuno) product for treatment of bleeding 129. Hay CR, Lozier JN, Lee CA, et al: Safety profile of porcine factor
episodes in hemophiliacs with inhibitors. Blood 61:36, 1983. VIII and its use as hospital and home-therapy for patients with